Martin Meglasson

Martin Meglasson has filed trades across 2 companies (mainly through SEC (Form 4)), most often in Ligand Pharmaceuticals Inc and Bellerophon Therapeutics, Inc. In total, 14 filings cover trades dated from 15 December 2006 to 20 May 2015.

In open-market terms, that means 6 purchases worth €155k on one side and 1 sale worth €46k on the other. On balance, insiders were net buyers of €110k. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. Outside the open market, there are 6 share grants and 1 option exercise. 2015 to date brings 2 purchases and no sales.

Half of the purchases are above €6,403 and half below. For 4 purchases whose 90-day window has closed, the share price was higher on day 90 than the day after publication in 0% of cases, with a median move of -7.6%. They describe history only and say nothing certain about the share price ahead.

The newest entry dates from 22 May 2015: an open-market purchase of €5,388, in Bellerophon Therapeutics, Inc. Filings reach the SEC (Form 4) feed a median of 3 days after the trade. For comparison, the SEC allows two business days to file a Form 4. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.